Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FB-RMSH-2
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
18F-FB-RMSH-2 is a fluorine-18 labeled radiopharmaceutical designed for positron emission tomography (PET) imaging of malignant melanoma. It is a specific isomer of the rhenium-cyclized metallopeptide Ac-d-Lys-ReCCMSH(Arg11), which is an analog of alpha-melanocyte-stimulating hormone (alpha-MSH). The compound targets the melanocortin type 1 receptor (MC1R), a protein frequently overexpressed in melanoma cells. By labeling the peptide with N-succinimidyl-4-18F-fluorobenzoate (18F-SFB), researchers created a probe that demonstrates high binding affinity and specific tumor uptake in preclinical models, such as the B16F10 murine melanoma model. Compared to its isomer 18F-FB-RMSH-1, this version exhibits slightly lower tumor uptake and higher accumulation in the liver and kidneys.
- Other names
- 18F-FB-Ac-d-Lys-ReCCMSH(Arg11) isomer 218F-labeled metallopeptide isomer 2
02
Targets
MC1R (Melanocortin Type 1 Receptor)
Beyond the preview
Go deeper on 18F-FB-RMSH-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FB-RMSH-2.